bioRxiv · 10.1101/2025.02.28.640879
Clinical progression of clonal hematopoiesis is determined by a combination of mutation timing, fitness, and clonal structure
Abstract
Clonal hematopoiesis (CH) is characterized by expanding blood cell clones carrying somatic mutations in healthy aged individuals and is associated with various age-related diseases and all-cause mortality. While CH mutations affect diverse genes associated with myeloid malignancies, their mechanisms of expansion and disease associations remain poorly understood. We investigate the relationship between clonal fitness and clinical outcomes by integrating data from three longitudinal aging cohorts (n=713, observations=2,341). We demonstrate pathway-specific fitness advantage and clonal composition influence clonal dynamics. Further, the timing of mutation acquisition is necessary to determine the extent of clonal expansion reached during the host individuals lifetime. We introduce MACS120, a metric combining mutation context, timing, and variant fitness to predict future clonal growth, outperforming traditional variant allele frequency measurements in predicting clinical outcomes. Our unified analytical framework enables standardized clonal dynamics inference across cohorts, advancing our ability to predict and potentially intervene in CH-related pathologies.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Latorre-Crespo, E., Robertson, N. A., Kosebent, G., Macgillivray, L., Murphy, L., Uddin, M., Honigberg, M., Whitsel, E. A., Bick, A. G., Reiner, A. P., Orru, V., Marongiu, M., Cucca, F., Fiorillo, E., Deary, I., Harris, S., Cox, S. R., Marioni, R., Schumacher, L., Chandra, T., Kirschner, K.. 2025-03-02. Clinical progression of clonal hematopoiesis is determined by a combination of mutation timing, fitness, and clonal structure. https://doi.org/10.1101/2025.02.28.640879
Cite the original work for its findings. Save a collection to share your selection of sources.